TY - JOUR
T1 - Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity
T2 - The HOPE-Combi survey
AU - Kario, Kazuomi
AU - Matsuda, Saori
AU - Nagahama, Shinobu
AU - Kurose, Yoshiki
AU - Sugii, Hitoshi
AU - Teshima, Tsukasa
AU - Suzuki, Noriyuki
N1 - Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - The home blood pressure (BP) control by a single-pill combination of cilnidipine (an L-/N-type calcium channel blocker; CCB) and valsartan (HOPE-Combi) survey is a multicenter, post-marketing, prospective observational study of a single-pill combination of cilnidipine 10 mg and valsartan 80 mg (SPC of Cil/Val) in patients with uncontrolled hypertension. We examined the effects of the SPC of Cil/Val on morning home systolic BP (MHSBP) and morning home pulse pressure (MHPP) of 1036 patients with hypertension over 12 months. MHSBP decreased by 14.0 mm Hg (P <.01), and MHPP decreased by 6.6 mm Hg (P <.01). Moreover, morning home pulse rate (MHPR) decreased by 2.1 bpm (P <.01). A more progressive and greater decrease in MHSBP (−17.2 vs −10.3 mm Hg, P <.01) and MHPP (−7.6 vs −4.9 mm Hg, P <.01) was observed in patients with higher MHPR (≥70 bpm) than in those with lower MHPR (<70 bpm) over the treatment period. In particular, in patients with a wide MHPP (≥70 mm Hg), the difference in the MHPP reduction was greater in patients with higher MHPR than in those with lower MHPR (−17.9 vs −13.6 mm Hg, P <.01). These results suggested that the SPC of Cil/Val, which possesses the unique sympatholytic characteristics of an L-/N-type CCB, was particularly effective in patients with uncontrolled hypertension and sympathetic hyperactivity.
AB - The home blood pressure (BP) control by a single-pill combination of cilnidipine (an L-/N-type calcium channel blocker; CCB) and valsartan (HOPE-Combi) survey is a multicenter, post-marketing, prospective observational study of a single-pill combination of cilnidipine 10 mg and valsartan 80 mg (SPC of Cil/Val) in patients with uncontrolled hypertension. We examined the effects of the SPC of Cil/Val on morning home systolic BP (MHSBP) and morning home pulse pressure (MHPP) of 1036 patients with hypertension over 12 months. MHSBP decreased by 14.0 mm Hg (P <.01), and MHPP decreased by 6.6 mm Hg (P <.01). Moreover, morning home pulse rate (MHPR) decreased by 2.1 bpm (P <.01). A more progressive and greater decrease in MHSBP (−17.2 vs −10.3 mm Hg, P <.01) and MHPP (−7.6 vs −4.9 mm Hg, P <.01) was observed in patients with higher MHPR (≥70 bpm) than in those with lower MHPR (<70 bpm) over the treatment period. In particular, in patients with a wide MHPP (≥70 mm Hg), the difference in the MHPP reduction was greater in patients with higher MHPR than in those with lower MHPR (−17.9 vs −13.6 mm Hg, P <.01). These results suggested that the SPC of Cil/Val, which possesses the unique sympatholytic characteristics of an L-/N-type CCB, was particularly effective in patients with uncontrolled hypertension and sympathetic hyperactivity.
KW - HOPE-Combi survey
KW - cilnidipine
KW - morning blood pressure
KW - morning pulse pressure
KW - single-pill combinations
KW - valsartan
UR - https://www.scopus.com/pages/publications/85083655832
U2 - 10.1111/jch.13771
DO - 10.1111/jch.13771
M3 - Article
C2 - 32311215
AN - SCOPUS:85083655832
SN - 1524-6175
VL - 22
SP - 457
EP - 464
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 3
ER -